MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company with a market capitalization of approximately $12.4 million, announced today that it has received U.S.

Management indicated that the launch of Leqselvi could be delayed until December 2026 if the company does not secure a favourable judgment in the ongoing patent infringement case.